Remdesivir-Induced Bradycardia in COVID-19: A Single Center Prospective Study.
作者信息
Attena Emilio, Albani Stefano, Maraolo Alberto Enrico, Mollica Mariano, De Rosa Annunziata, Pisapia Raffaella, Fiorentino Giuseppe, Parrella Roberto, Severino Sergio, Russo Vincenzo
机构信息
Division of Cardiology (E.A., S.S.), Cotugno Hospital- A.O.R.N. Dei Colli, Naples.
Division of Cardiology, Umberto Parini Hospital, Aosta, Aosta Valley (S.A.).
出版信息
Circ Arrhythm Electrophysiol. 2021 Jul;14(7):e009811. doi: 10.1161/CIRCEP.121.009811. Epub 2021 Jun 29.
Abstract
摘要
相似文献
1
Remdesivir-Induced Bradycardia in COVID-19: A Single Center Prospective Study.瑞德西韦致新型冠状病毒肺炎患者心动过缓：一项单中心前瞻性研究
Circ Arrhythm Electrophysiol. 2021 Jul;14(7):e009811. doi: 10.1161/CIRCEP.121.009811. Epub 2021 Jun 29.
2
Bradycardia associated with remdesivir therapy for COVID-19 in a 59-year-old man.一名59岁男性在接受瑞德西韦治疗新型冠状病毒肺炎时出现心动过缓。
CMAJ. 2021 Apr 26;193(17):E612-E615. doi: 10.1503/cmaj.210300.
3
Potential remdesivir-related transient bradycardia in patients with coronavirus disease 2019 (COVID-19).2019冠状病毒病（COVID-19）患者中与瑞德西韦相关的潜在短暂性心动过缓
J Med Virol. 2021 May;93(5):2631-2634. doi: 10.1002/jmv.26898. Epub 2021 Mar 3.
4
Safety and effectiveness of remdesivir in hospitalized patients with COVID-19 and severe renal impairment: experience at a large medical center.瑞德西韦在 COVID-19 住院患者和严重肾功能损害患者中的安全性和有效性：一家大型医疗中心的经验。
Ann Med. 2024 Dec;56(1):2361843. doi: 10.1080/07853890.2024.2361843. Epub 2024 Jun 3.
5
Assessment of adverse events associated with remdesivir use for coronavirus disease 2019 using real-world data.使用真实世界数据评估瑞德西韦治疗 2019 冠状病毒病相关不良反应。
Expert Opin Drug Saf. 2021 Dec;20(12):1559-1564. doi: 10.1080/14740338.2021.1962846. Epub 2021 Aug 5.
6
Remdesivir-associated bradycardia might be a sign of good prognosis in COVID-19 patients.瑞德西韦相关的心动过缓可能是新冠肺炎患者预后良好的一个迹象。
Clin Microbiol Infect. 2022 Apr;28(4):619. doi: 10.1016/j.cmi.2021.12.017. Epub 2022 Jan 6.
7
Clinical Characteristics and Implications of Bradycardia in COVID-19 Patients Treated with Remdesivir: A Single-Center Retrospective Cohort Study.瑞德西韦治疗的 COVID-19 患者心动过缓的临床特征及意义：一项单中心回顾性队列研究。
Clin Drug Investig. 2022 Sep;42(9):763-774. doi: 10.1007/s40261-022-01187-x. Epub 2022 Aug 17.
8
Remdesivir-Related Cardiac Adverse Effects in COVID-19 Patients: A Case-Control Study.瑞德西韦相关的 COVID-19 患者心脏不良事件：一项病例对照研究。
Drug Res (Stuttg). 2024 Jul;74(6):290-295. doi: 10.1055/a-2332-3253. Epub 2024 Jul 5.
9
Remdesivir-induced symmetrical drug-related intertriginous and flexural exanthema (SDRIFE)? A case report with review of the literature.瑞德西韦诱发的对称性药物相关性擦烂和屈侧疹（SDRIFE）？一例病例报告并文献复习
Eur J Clin Pharmacol. 2021 Jan;77(1):141-144. doi: 10.1007/s00228-020-02955-4. Epub 2020 Aug 6.
10
Remdesivir Use in COVID-19 Patients: Cutaneous Adverse Effect or Disease Manifestation?瑞德西韦在新冠肺炎患者中的应用：皮肤不良反应还是疾病表现？
J Drugs Dermatol. 2021 May 1;20(5):575. doi: 10.36849/JDD.5777.
引用本文的文献
1
Cardiac adverse events associated with remdesivir in COVID-19 patients: a systematic review and meta-analysis of randomised controlled trials.新冠患者中与瑞德西韦相关的心脏不良事件：随机对照试验的系统评价和荟萃分析
BMJ Open. 2025 Jul 18;15(7):e089977. doi: 10.1136/bmjopen-2024-089977.
2
Real-world experience with therapies for SARS-CoV-2: Lessons from the Italian COVID-19 studies.SARS-CoV-2治疗的真实世界经验：来自意大利COVID-19研究的教训。
Infez Med. 2025 Mar 1;33(1):64-75. doi: 10.53854/liim-3301-6. eCollection 2025.
3
Incidence of bradycardia with the use of remdesivir for coronavirus disease of 2019 and risk factor analysis.使用瑞德西韦治疗2019冠状病毒病时心动过缓的发生率及危险因素分析。
Int J Crit Illn Inj Sci. 2024 Oct-Dec;14(4):203-207. doi: 10.4103/ijciis.ijciis_57_24. Epub 2024 Dec 23.
4
Cardiac Arrhythmias and Autonomic Dysfunction Associated With COVID-19: A Scientific Statement From the American Heart Association.与 COVID-19 相关的心律失常和自主神经功能障碍：美国心脏协会的科学声明。
Circulation. 2024 Nov 19;150(21):e449-e465. doi: 10.1161/CIR.0000000000001290. Epub 2024 Oct 14.
5
The inciting factor for bradycardia in COVID-19 patients: a potential harm of steroid treatment.新冠病毒肺炎患者心动过缓的诱发因素：类固醇治疗的潜在危害
J Thorac Dis. 2024 May 31;16(5):2835-2844. doi: 10.21037/jtd-23-1382. Epub 2024 May 10.
6
Remdesivir-Induced Bradycardia and Mortality in SARS-CoV-2 Infection, Potential Risk Factors Assessment: A Systematic Review and Meta-Analysis.瑞德西韦在新冠病毒感染中导致的心动过缓和死亡率：潜在风险因素评估——一项系统评价与荟萃分析
J Clin Med. 2023 Dec 5;12(24):7518. doi: 10.3390/jcm12247518.
7
Adverse Events in Pregnant Patients Treated with Coronavirus Disease 2019 Therapeutics.妊娠期新型冠状病毒 2019 治疗药物的不良反应。
J Med Toxicol. 2023 Oct;19(4):381-388. doi: 10.1007/s13181-023-00961-3. Epub 2023 Aug 15.
8
Bradycardia and Outcomes in COVID-19 Patients on Remdesivir: A Multicenter Retrospective Study.接受瑞德西韦治疗的COVID-19患者的心动过缓和预后：一项多中心回顾性研究。
Cardiol Res. 2023 Jun;14(3):192-200. doi: 10.14740/cr1493. Epub 2023 May 26.
9
Remdesivir-associated bradycardia in COVID-19: a rapid review protocol.瑞德西韦相关 COVID-19 患者的心动过缓：快速综述方案。
BMJ Open. 2023 May 31;13(5):e068564. doi: 10.1136/bmjopen-2022-068564.
10
Complicated appendicitis, acute pancreatitis, pleural effusion, and sinus bradycardia in a COVID-19 patient.一名新冠肺炎患者出现复杂性阑尾炎、急性胰腺炎、胸腔积液和窦性心动过缓。
Clin Case Rep. 2023 Mar 8;11(3):e7077. doi: 10.1002/ccr3.7077. eCollection 2023 Mar.
本文引用的文献
1
Marked Sinus Bradycardia Associated With Remdesivir in COVID-19: A Case and Literature Review.瑞德西韦治疗新型冠状病毒肺炎相关的显著窦性心动过缓：1例病例及文献综述
JACC Case Rep. 2020 Nov 18;2(14):2260-2264. doi: 10.1016/j.jaccas.2020.08.025. Epub 2020 Oct 28.
2
Remdesivir: Review of Pharmacology, Pre-clinical Data, and Emerging Clinical Experience for COVID-19.瑞德西韦：针对 COVID-19 的药理学、临床前数据和新兴临床经验综述。
Pharmacotherapy. 2020 Jul;40(7):659-671. doi: 10.1002/phar.2429. Epub 2020 Jun 28.
3
Remdesivir for the Treatment of Covid-19 - Final Report.瑞德西韦治疗 COVID-19 的疗效 - 最终报告。
N Engl J Med. 2020 Nov 5;383(19):1813-1826. doi: 10.1056/NEJMoa2007764. Epub 2020 Oct 8.
Zotero 插件